Furthermore, the administration of P2Y12 shRNA could significantly reduce visceral pain and depression in IBD mice and significantly down-regulate the levels of interleukin-1beta in the mPFC of mice, thus inhibiting microglial activation. Here, P2RY12 is linked to irritable bowel syndrome.